

RADIOPHARM ACQUIRES IP OWNERSHIP OF THREE RADIOPHARMACEUTICAL NANOBODIES

- Promising therapeutic applications in addition to imaging
- Allows RAD unfettered global rights to partner or sub-license & secures direct ownership chain to patents
- Targeting highly relevant solid tumor pathways inc. HER-2, TROP-2 and PTK7
- Worldwide IP ownership is in addition to the worldwide licenses of the technology already owned by RAD

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has acquired full intellectual property (IP) ownership to three assets to target diagnosis and treatment of a range of solid tumors.

Radiopharm will acquire the patents to three different nanobodies from NanoMab Technology Ltd (NanoMab), targeting HER-2 (breast cancer), TROP-2 (triple negative breast cancer, or TNBC) and PTK7 (multiple solid tumours).

Nano-mAbs are made using genetically engineered camelid derived single domain antibodies (sdAb), that can be labelled with radioisotopes to diagnose and treat multiple tumor types.

Radiopharm has been using NanoMab nanobodies under a licence agreement in its Phase 1 clinical trials and pre-clinical studies.

As announced in December, a Phase 1 study investigating the safety, dosimetry and efficacy of the RAD201 asset, targeting HER-2 positive breast cancer subjects, was completed with the Company’s collaborators at Shanghai General Hospital and NanoMab.

Results from the Phase 1 clinical studies completed to date have indicated the potential to use NanoMab’s nanobodies for imaging and treatment of HER-2+ cancers with different medical radioisotopes. Final candidate selection for TROP2 and PTK7 is underway and expected soon.

Radiopharm Theranostics Managing Director and CEO Riccardo Canevari said the Company’s decision to acquire the IP for three NanoMab assets was based on the high potential of nanobody technology in both diagnostic and therapeutic applications.

“Acquiring the IP for these assets supports Radiopharm’s strategy to focus on innovation and it will allow us to further accelerate clinical development of these multiple assets,” he said.

“We are excited to build on our existing portfolio of worldwide IP rights with these assets from Nanomab Technology Ltd.”

Consideration for the acquisition of the NanoMab IP will be the issue of US\$500,000 in fully paid ordinary shares of Radiopharm Theranostics.

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

**ASX ANNOUNCEMENT
24 JANUARY 2022**



For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>